Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Paclitaxel to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced or Metastatic Solid Tumors

WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 23, 2018– Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a